Accès ouvert déclaré
2025
article
Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort
Alessandra Vergori, Alessandro Cozzi-Lepri, Sergio Lo Caputo, Alessandro Tavelli, Valentina Mazzotta, Elisabetta Schiaroli, Giancarlo Orofino, Cristina Mussini, Silvia Nozza, Antonella Cingolani, Andrea Antinori, Antonella d’Arminio Monforte, Antonella d’Arminio Monforte, A Antinori, Spinello Antinori, A Castagna, R Cauda, Giovanni Di Perri, E Girardi, R Iardino, Adriano Lazzarin, Giulia Marchetti, C Mussini, E Quiros-Roldan, L Sarmati, Barbara Suligoi, F von Schloesser, P. Viale, F Ceccherini-Silberstein, A Cozzi-Lepri, A Di Biagio, Enrico Girardi, A Gori, F Maggiolo, C Mussini, Massimo Puoti, Carlo Federico Perno, C Torti, Alessandra Bandera, S Bonora, A Calcagno, Diana Canetti, Antonella Castagna, A Cervo, Paola Cinque, A Cozzi-Lepri, Roberta Gagliardini, A Giacomelli, Nicola Gianotti, Alessandra Gori, Giovanni Guaraldi, Simone Lanini, Giuseppe Lapadula, Miriam Lichtner, Alessia Lai, G Madeddu, Vincenzo Malagnino, G Marchetti, Annalisa Mondi, Stefania Piconi, Carmela Pinnetti, Eugenia Quirós-Roldán, Roberto Rossotti, S Rusconi, Maria Mercedes Santoro, A Saracino, Vincenzo Spagnuolo, N Squillace, Valentina Svicher, L Taramasso, S De Benedittis, Iuri Fanti, Nicolò Lentini, M Giotta, R Pastorino, A Rodano’, Ashley Roen, S Bazzichetto, Massimo Cernuschi, L Cosmaro, A Perziano, Valeria Calvino, Danilo Russo, M Farinella, Nicoletta Policek, V L Del Negro, Matteo Augello, Silvia Carrara, Silvia Graziano, Gennaro Prota, S Truffa, Donatella Vincenti, Roberta Rovito, Andrea Giacometti, Andrea Costantini, V Barocci, Carmen Rita Santoro, Eugenio Milano, Laura Comi, Claudia Suardi, Lorenzo Badia, Silvia Cretella, E M Erne, Angela Pieri, Emanuele Focà, B Menzaghi, C Abeli, Luchino Chessa, Francesco Pes, Paolo Maggi, Loredana Alessio, Giuseppe Nunnari, Benedetto Maurizio Celesia, J Vecchiet, Katia Falasca, Angelo Pan, Sarah Dal Zoppo, Daniela Segala, Filippo Bartalesi, Alessandro Bartoloni, Beatrice Borchi, Cecilia Costa, A Narducci, M. Bassetti, Emanuele Pontali, Sabrina Blanchi, Nicoletta Bobbio, Cosmo Del Borgo, R. Marocco, G Mancarella, Chiara Molteni, G Canavesi, G Pellicanò, Ylenia Russotto, Valeria Bono, Maria Vittoria Cossu, Riccardo Lolatto, M C Moioli, Laura Pezzati, S Diotallevi, Camilla Tincati, Marianna Menozzi, Paolo Bonfanti, Vincenzo Sangiovanni, Ivan Gentile, V Esposito, Nicola Coppola, Francesco Maria Fusco, Giovanni Di Filippo, V Rizzo, N Sangiovanni, Salvatore Martini, Anna Maria Cattelan, D Leoni, Antonio Cascio, Marcello Trizzino, D Francisci, Giustino Parruti, Federica Sozio, D Messeri, Sara Irene Bonelli, C Lazzaretti, R Corsini, Claudio Maria Mastroianni, Alessandra Latini, Ilaria Mastrorosa, Silvia Lamonica, M Capozzi, Marta Camici, Ivano Mezzaroma, Marco Rivano Capparuccia, Giancarlo Iaiani, C Stingone, L Gianserra, Jessica Paulicelli, Maria Maddalena Plazzi, G d’Ettore, Marisa Fusto, I Coledan, Andrea De Vito, Massimiliano Fabbiani, Francesca Montagnani, Antonina Franco, Rosario Vecchio, C Di Giuli, G Orofino, Guido Calleri, Giacomo Accardo, Carlo Tascini, AP Londero, Giuliana Battagin, S Nicolè, Giulio Starnini, S Dell’Isola
2Citations signalées — pas une note de qualité
14Institutions déclarées
3Pays d’affiliation déclarés
Résumé fourni par la source
OBJECTIVES: This analysis aimed to evaluate the rate of failure of first-line lamivudine/dolutegravir in a real-world setting and assess the effectiveness among people with HIV (PWH) at higher risk of suboptimal response. METHODS: The study included PWH from the ICONA cohort who started first-line lamivudine/dolutegravir between 2016 and 2024. The primary endpoint was time to treatment failure (TF), defined as virological failure (VF, two consecutive HIV-RNA of >50 copies/mL >6 months after treatment initiation) or discontinuation due to toxicity/lack virological control/non-adherence or death for any cause. Secondary endpoints were time to treatment discontinuation for any reason (TD) and pure VF. Main exposures of interest were baseline CD4 and HIV-RNA, age, sex at birth and nation of birth. Standard survival analysis and Cox regression models were used. RESULTS: Among 446 participants, after a median follow-up of 22 months, 4.3% (n = 19) experienced TF, the 3 year cumulative probability was 5.8% (95% CI: 2.9%-8.7%). Baseline CD4 count was associated with a 3-fold higher risk of TF, which decreased after adjustments. Higher viral loads (>100 000 copies/mL), age >50 years and foreign-born status were also associated with an increased risk of TF. No differences in TF according to sex at birth were found. By 3 years the probabilities of TD and VF were 13.4% (95% CI: 9.1%-17.6%) and 2.3% (95% CI: 0.19%-4.4%), respectively. CONCLUSIONS: In our real-world setting, the TF probability for first-line lamivudine/dolutegravir was below 6% at 3 years, lower than in randomized trials. Our data suggest that, as shown with other regimens, PWH starting lamivudine/dolutegravir with CD4 count of ≤200 cells/mm3, HIV-RNA of >100 000 copies/mL, older age or foreign-born status may be at higher risk of TF, though larger studies are needed to qualify the magnitude of the effect.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort
- Date Crossref
- 23/09/2025
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.
Institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.
Sujets associés
HIV/AIDS drug development and treatmentHIV/AIDS Research and InterventionsHIV Research and Treatment